Makers of Wegovy and Ozempic issue warning over deadly weight-loss copycats

Healthcare giant Novo Nordisk has said it was aware of reports of 10 deaths and 100 people left in hospital who had taken compounded copies of its weight-loss and diabetes drugs.

U.S. regulations allow compounding pharmacies to copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand.

Novo Nordisk’s popular weight-loss injection Wegovy and diabetes drug Ozempic, both known chemically as semaglutide, were until recently in shortage in the United States.

Given all the regulatory surveillance of Novo Nordisk’s production of the two drugs, CEO Lars Fruergaard Jorgensen said it was puzzling that people in the United States could inject themselves with a product that was not regulated, approved or inspected.

Read full story

Source: The Independent, 7 November 2024